Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital biomarkers

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

- PMLiVE

Two UK clinical trials launched to identify blood tests for dementia diagnosis

The neurodegenerative condition affects more than 944,000 people in the UK

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment

Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Researchers develop new blood test to identify risk of Parkinson’s disease

The findings could help to identify people most likely to benefit from disease-modifying therapies

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

Newel Health launches study of digital therapeutic for Parkinson’s disease

The Soturi app is designed to optimise personalised treatment plans for patients

- PMLiVE

Spinal stimulation implant offers new hope for Parkinson’s disease treatment

The implant was tested to correct gait disorders associated with advanced cases of the disease

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links